Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy

Journal of Clinical Investigation

Volumn 111, Issue 6, 2003, Pages 859-867

  Song, Qiujing ^a   Schmidt, Albrecht G ^a   Hahn, Harvey S ^a   Carr, Andrew N ^a   Frank, Beate ^a   Pater, Luke ^a   Gerst, Mike ^a   Young, Karen ^a   Hoit, Brian D ^b   McConnell, Bradley K ^c   Haghighi, Kobra ^a   Seidman, Christine E ^c   Seidman, Jonathan G ^c   Dorn II, Gerald W ^a   Kranias, Evangelia G ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCINEURIN; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY MUTANT MYOSIN BINDING PROTEIN C; JANUS KINASE; MYOSIN BINDING PROTEIN C; PHOSPHOLAMBAN; PROTEIN; UNCLASSIFIED DRUG; CALCIUM; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; CONNEXIN 43; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MYOSIN-BINDING PROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CYCLING; CALCIUM TRANSPORT; CONTROLLED STUDY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GALPHA Q GENE; GENE; GENE OVEREXPRESSION; GENETIC MODEL; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; ANIMAL; CARDIOMEGALY; CONGESTIVE HEART FAILURE; GENETICS; HEART CONTRACTION; HEART MUSCLE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CALCINEURIN; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CARRIER PROTEINS; CONNEXIN 43; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEART FAILURE, CONGESTIVE; HETEROTRIMERIC GTP-BINDING PROTEINS; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; SARCOPLASMIC RETICULUM;

EID: 0037362850     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200316738     Document Type: Article

References (48)

1. Ho, K.K., Pinsky, J.L., Kannel, W.B., and Levy, D. 1993. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 22:6-13.
2. Hasenfuss, G., et al. 1997. Calcium handling proteins in the failing human heart. Basic. Res. Cardiol. 92(Suppl. 1):87-93.
3. Houser, S.R., Piacentino, V., 3rd, and Weisser, J. 2000. Abnormalities of calcium cycling in the hypertrophied and failing heart. J. Mol. Cell. Cardiol. 32:1595-1607.
4. 2+-ATPase in a rat model of heart failure. Circulation. 104:1424-1429.
5. del Monte, F., Harding, S.E., Dec, G.W., Gwathmey, J.K., and Hajjar, R.J. 2002. Targeting phospholamban by gene transfer in human heart failure. Circulation. 26:904-907.
6. Luo, W., et al. 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ. Res. 75:401-409.
7. Desai, K.H., Schauble, E., Luo, W., Kranias, E., and Bernstein, D. 1999. Phospholamban deficiency does not compromise exercise capacity. Am. J. Physiol. 276:H1172-H1177.
8. Slack, J.P., et al. 2001. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J. Mol. Cell. Cardiol. 33:1031-1040.
9. Wolska, B.M., et al. 2002. Expression of slow skeletal troponin 1 in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation. Circ. Res. 90:882-888.
10. Pi, Y., Kemnitz, K.R., Zhang, D., Kranias, E.G., and Walker, J.W. 2002. Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ. Res. 90:649-656.
11. Sato, Y., et al. 2001. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J. Biol. Chem. 276:9392-9399.
12. Zhao, W., et al. 2003. Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state. Cardiovasc. Res 57:71-81.
13. Freeman, K., et al. 2001. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J. Clin Invest. 107:967-974.
14. Minamisawa, S., et al. 1999. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 99:313-322.
15. Hoshijima, M., et al. 2002. Chronic suppression of heart-failure progression by a pesudephosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8:864-871.
16. D'Angelo, D.D., et al. 1997. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. U. S. A. 94:8121-8126.
17. Akhter, S.A., et al. 1998. Targeting the receptor-Gαq interference to inhibit in vivo pressure overload myocardial hypertrophy. Science 280:574-577.
18. McConnell, B.K., et al. 1999. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J. Clin. Invest. 104:1235-1244.
19. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press. Washington, D.C., USA. 125 pp.
20. 2- indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440-3450.
21. Mochly-Rosen, D., et al. 2000. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKC epsilon translocation. Circ. Res. 86:1173-1179.
22. Opie, L.H. 1991. The heart: physiology and metabolism. Raven Press. New York, New York, USA. 322-332.
23. Sakata, Y., Hoit, B.C., Liggett, S.B., Walsh, R.A., and Dorn, G.W., 2nd. 1998. Decompensation of pressure-overload hypertrophy in Gα q-overexpressing mice. Circulation. 97:1488-1495.
24. Kiss, E., et al. 1997. β-adrenergic regulation of cAMP and protein phosphorylation in phospholamban-knockout mouse hearts. Am. J. Physiol. 272:H785-H790.
25. Minamino, T., et al. 2002. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gαq. Proc. Natl. Acad. Sci. U. S. A. 99:3866-3871.
26. Petrich, B.G., et al. 2002. c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ. Res. 91:640-647.
27. Ai, Z., Fischer, A., Spray, D.C., Brown, A.M., and Fishman, G.I. 2000. Wnt-1 regulation of connexin43 in cardiac myocytes. J. Clin. Invest. 105:161-171.
28. Ferreira-Cornwell, M.C., et al. 2002. Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart. J. Cell. Sci. 115:1623-1634.
29. Mende, U., et al. 1998. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl. Acad. Sci. U. S. A. 95:13893-13898.
30. De Windt, L.J., Lim, H.W., Haq, S., Force, T., and Molkentin, J.D. 2000. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J. Biol. Chem. 275:13571-13579.
31. Marks, A.R. 2000. Cardiac intracellular calcium release channels: role in heart failure. Circ. Res. 87:8-11.
32. 2+ oscillations. Science. 279:227-230.
33. Arber, S., et al. 1997. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 88:393-403.
34. Delling, U., Sussman, M.A., and Molkentin, J.D. 2000. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat. Med. 6:942-943.
35. Sussman, M.A., et al. 1999. Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice. Am. J. Pathol. 155:2101-2113.
36. Rogers, J.H., et al. 2001. RGS4 reduces contractile dysfunction and hypertrophic gene expression in Gαq overexpressing mice. J. Mol. Cell. Cardiol. 33:209-218.
37. Wu, G., Toyokawa, T., Hahn, H., and Dorn, G.W., 2nd. 2000. Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Gαq. Biol. Chem. 275:29927-29930.
38. 2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq overexpressing mice. Proc. Natl. Acad. Sci. U. S. A. 96:6400-6405.
39. Tepe, N.M., and Liggett, S.B. 1999. Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of β-adrenergic receptor dysfunction in the Gαq overexpressing mouse. FEBS Lett. 458:236-240.
40. Yussman, M.G., et al. 2002. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat. Med. 8:725-730.
41. Yang, Q., et al. 1999. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ. Res. 85:841-847.
42. Winegrad, S. 1999. Cardiac myosin binding protein C. Circ. Res. 84:1117-1126.
43. McClellan, G., Kulikovskaya, I., and Winegrad, S. 2001. Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys. J. 81:1083-1092.
44. Kunst, G., et al. 2000. Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ. Res. 86:51-58.
45. Chu, G., et al. 1996. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. 79:1064-1076.
46. 2+ channel currents in mouse ventricular myocytes. Am. J. Physiol. 272:H606-H612.
47. 2+-sensitivity or myosin ATPase-activity of the contractile proteins. Basic Res. Cardiol. 95:12-18.
48. 2+] (i) restores uncoupled beta-adrenergic signaling in isolated perfused transgenic mouse hearts. Circ. Res. 88:9-11.